Free Trial
OTCMKTS:UCBJF

UCB (UCBJF) Stock Price, News & Analysis

UCB logo
$198.28 +2.38 (+1.21%)
(As of 05:51 PM ET)

About UCB Stock (OTCMKTS:UCBJF)

Key Stats

Today's Range
$198.28
$198.28
50-Day Range
$174.00
$195.90
52-Week Range
$87.10
$198.28
Volume
80 shs
Average Volume
296 shs
Market Capitalization
$37.48 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

UCB SA, a biopharmaceutical company, develops products and solutions for people with neurology and immunology diseases worldwide. The company's primary products include Cimzia for inflammatory TNF mediated diseases, as well as ankylosing spondylitis, axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, and rheumatoid arthritis; Vimpat, Keppra, and Briviact for epilepsy; Neupro for Parkinson's disease and restless legs syndrome; Nayzilam, a nasal spray rescue treatment for epilepsy seizure clusters; and Zyrtec and Xyzal for allergies. It also offers Evenity for the treatment of osteoporosis in postmenopausal women; Bimzelx for treating plaque psoriasis, psoriatic arthritis, and axial spondyloarthritis; and Fintepla to treat Dravet syndrome. In addition, the company is involved in developing rozanolixizumab and Zilbrisq to treat myasthenia gravis; dapirolizumab pegol for systemic lupus erythematosus; fenfluramine to treat CDKL5 deficiency disorder; doxecitine for TK2 deficiency disorder; STACCATO alprazolam for stereotypical prolonged seizures; bepranemab to treat Alzheimer's disease; minzasolmin and UCB0222 for Parkinson's disease; and UCB1381 and UCB9741 for atropic dermatitis. Further, it engages in contract manufacturing activities. UCB SA has collaboration agreements with Amgen, Biogen, Roche/Genentech, Novartis, and Otsuka. The company was incorporated in 1925 and is headquartered in Brussels, Belgium.

Receive UCBJF Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for UCB and its competitors with MarketBeat's FREE daily newsletter.

UCBJF Stock News Headlines

UCB price target raised to EUR 215 from EUR 200 at Deutsche Bank
UBS Remains a Buy on UCB SA (0NZT)
2025 AI Stock Picks: 2 Hidden Gems Under $10/Share
The AI sector continues to make waves as we move into 2025, and now is a prime opportunity to get involved—without stretching your budget! We’ve just uncovered 2 promising AI stocks trading for under $10/share, and they’re positioned for impressive growth in the coming months.
Artisan Global Equity Fund Q3 2024 Commentary
Artisan International Fund Q3 2024 Commentary
Barclays Keeps Their Buy Rating on UCB SA (0NZT)
See More Headlines

UCBJF Stock Analysis - Frequently Asked Questions

UCB's stock was trading at $87.10 at the beginning of 2024. Since then, UCBJF stock has increased by 127.6% and is now trading at $198.2750.
View the best growth stocks for 2024 here
.

Shares of UCBJF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Company Calendar

Today
12/23/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
OTCMKTS:UCBJF
Employees
9,083
Year Founded
1928

Profitability

Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$5.27 billion
Cash Flow
$8.41 per share
Book Value
$50.52 per share

Miscellaneous

Free Float
N/A
Market Cap
$37.03 billion
Optionable
Not Optionable
Beta
0.47

Social Links

12 Stocks Corporate Insiders are Abandoning Cover

If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?

Get This Free Report

This page (OTCMKTS:UCBJF) was last updated on 12/23/2024 by MarketBeat.com Staff
From Our Partners